Pfizer ended the Clinical Rrial for a Diabetes Pill
Pfizer ended the clinical trial for a diabetes pill called lotiglipron because they say that it was leading to elevated enzymes in the liver. Pfizer says that it will instead focus on its obesity drug called danuglipron. That’s interesting because the obesity drug market is super hot right now. On Monday, Eli Lilly presented findings claiming that their obesity treatment could help people lose a quarter of their body weight in 11 months. Drug makers are rushing to compete with the viral popularity of Ozempic and Mounjaro.
Credit to : Redacted
Please support our Sponsors here :
